Wyeth, Amgen Face Patent Suit Over Enbrel

Law360, New York (October 28, 2009, 5:58 PM EDT) -- A British charitable trust has slapped Amgen Inc. and Pfizer Inc. subsidiary Wyeth with a lawsuit over the lucrative rheumatoid arthritis drug Enbrel, accusing the two defendants — which co-market Enbrel in the U.S. — of willfully infringing a single patent and ignoring demands for royalty payments.

The Mathilda and Terence Kennedy Institute of Rheumatology Trust filed the complaint in the U.S. District Court for the District of Delaware on Tuesday, seeking treble damages and injunctive relief.

The trust has already licensed the patent-at-issue to Johnson...
To view the full article, register now.